Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 324 participants.
Also called NCT06220032
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 324 participants
- Registry
-
NCT06220032
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Netherlands
- Registry status
- Recruiting
Technical summary
Registry record NCT06220032. Randomized; no masking; primary purpose treatment. Start 2024-08-15 (actual); primary completion 2028-12-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
- Acronym
- HO170DLBCL
- Condition
- DLBCL - Diffuse Large B Cell Lymphoma
- Intervention (Drug)
- Dexrazoxane
- Intervention (Drug)
- Rituximab
- Intervention (Drug)
- Cyclophosphamide
- Intervention (Drug)
- Doxorubicin
- Intervention (Drug)
- Vincristine
- Intervention (Drug)
- Prednisolone
- Intervention (Drug)
- Lenalidomide
- Intervention (Drug)
- Pegfilgrastim
- Lead sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- Collaborator
- UMC Utrecht
- Collaborator
- Amsterdam UMC, location VUmc
- Collaborator
- The Dutch Network for Cardiovascular Research (WCN)
Record details
- Record id
cardio:ct-nct06220032- Content hash
029f10f421a2e98ddf6f71f0d7000a4c00cb60210971cf273527ffcb0ab615e5